Back to Search
Start Over
Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixafor
- Source :
- BONE MARROW TRANSPLANTATION, r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau, instname, Bone Marrow Transplantation, Dipòsit Digital de la UB, Universidad de Barcelona
- Publication Year :
- 2020
- Publisher :
- NATURE PUBLISHING GROUP, 2020.
-
Abstract
- Plerixafor + granulocyte-colony stimulating factor (G-CSF) is administered to patients with lymphoma who are poor mobilizers of hematopoietic stem cells (HSCs) in Europe. This international, multicenter, non-interventional registry study (NCT01362972) evaluated long-term follow-up of patients with lymphoma who received plerixafor for HSC mobilization versus other mobilization methods. Propensity score matching was conducted to balance baseline characteristics between comparison groups. The following mobilization regimens were compared: G-CSF + plerixafor (G + P) versus G-CSF alone; G + P versus G-CSF + chemotherapy (G + C); and G-CSF + plerixafor + chemotherapy (G + P + C) versus G + C. The primary outcomes were progression-free survival (PFS), overall survival (OS), and cumulative incidence of relapse (CIR). Overall, 313/3749 (8.3%) eligible patients were mobilized with plerixafor-containing regimens. After propensity score matching, 70 versus 36 patients were matched in the G + P versus G-CSF alone cohort, 124 versus 124 in the G + P versus G + C cohort, and 130 versus 130 in the G + P + C versus G + C cohort. For both PFS and OS, the upper bound of confidence interval for the hazard ratio was >1.3 for all comparisons, implying that non-inferiority was not demonstrated. No major differences in PFS, OS, and CIR were observed between the plerixafor and comparison groups.
- Subjects :
- Oncology
medicine.medical_specialty
Limfomes
Benzylamines
Immunopathogenesis
Lymphoma
Stem cells
030204 cardiovascular system & hematology
Cyclams
Article
03 medical and health sciences
0302 clinical medicine
Bone Marrow
Heterocyclic Compounds
Internal medicine
medicine
Humans
Cumulative incidence
Registries
Transplantation
Marrow transplantation
business.industry
Plerixafor
Stem-cell therapies
Hazard ratio
Hematology
medicine.disease
Confidence interval
Hematopoietic Stem Cell Mobilization
Europe
Propensity score matching
Cohort
Lymphomas
Neoplasm Recurrence, Local
business
Cèl·lules mare
030215 immunology
medicine.drug
Subjects
Details
- ISSN :
- 02683369
- Database :
- OpenAIRE
- Journal :
- BONE MARROW TRANSPLANTATION, r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau, instname, Bone Marrow Transplantation, Dipòsit Digital de la UB, Universidad de Barcelona
- Accession number :
- edsair.doi.dedup.....6d258ee8e4d1fe2cc3f09f82ad7b7bcf